GRAMPIAN HEALTH BOARD (NHS GRAMPIAN)
Department of Medical Oncology
NHS Grampian provides healthcare services for 500,000 people (North-East Scotland). The R&D dept works closely with the hospital and University of Aberdeen. The University is at the forefront of teaching and research in the humanities, medicine and sciences. Successes include: 4 Nobel Prizes; the generation of several biotech companies; 89% of Aberdeen’s research rated as ‘international quality ’in the UK 2008 RAE, >600 grants funded by the European Commission, schemes such (ESF), Socrates.
Key staff of the partner
Dr Marianne Nicolson, consultant medical oncologist in Aberdeen Royal Infirmary (ARI) for many years has been active in leading as CI or PI numerous successfully recruiting commercially or NCRI sponsored clinical trials in lung cancer.
Dr Nicolson is local and North of Scotland network lead clinician for thoracic cancers, also treating mesothelioma, melanoma, neuroendocrine tumours and hepatobiliary cancers. She chairs the UK NCRI lung cancer clinical studies group which oversees a portfolio of several trials in lung cancer and Mesothelioma.She was part of the development group that proposed the SIGN Guidelines on Lung Cancer (2005).
Professor Keith Kerr, lead thoracic pathologist, who is internationally respected for his published work.
Dr Raj Shrimali is a recently appointed clinical oncologist who is co-investigator for lung cancer trials, developing a major interest in specialized thoracic radiotherapy techniques.
There is a team of full time research nurses, pharmacists and data managers based in the oncology department at ARI.
Respiratory physicians, thoracic surgeons, specialist lung cancer nurses, radiologists – all who are involved in lung cancer diagnosis and management meet weekly at the multidisciplinary meeting.